Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 3/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13870640 | 0.84 | HTT (0.61) | HTTSMN1; SMN2ALDH1A1CYP3A4HPGD | |
| SCHEMBL13870776 | 0.83 | HTT (0.44) | HTTSMN1; SMN2ALDH1A1CYP3A4HPGD | |
| SCHEMBL13212086 | 0.75 | L3MBTL1 (0.47) | HTTSMN1; SMN2ALDH1A1CYP3A4HPGD | |
| SCHEMBL13853642 | 0.72 | NAMPT (0.45) | HTTSMN1; SMN2ALDH1A1LMNAKDM4E | |
| SCHEMBL13870783 | 0.72 | HTT (0.35) | HTTSMN1; SMN2ALDH1A1HPGDLMNA | |
| SCHEMBL24015858 | 0.71 | KDM4E (0.44) | SMN1; SMN2ALDH1A1CYP3A4HPGDLMNA | |
| SCHEMBL2844335 | 0.70 | KDM4E (0.40) | SMN1; SMN2ALDH1A1HPGDLMNAHSD17B10 | |
| SCHEMBL4076546 | 0.70 | ALDH1A1 (0.44) | HTTSMN1; SMN2ALDH1A1CYP3A4HPGD | |
| SCHEMBL11826578 | 0.70 | HSP90AB1 (0.44) | SMN1; SMN2ALDH1A1HPGDLMNAKDM4E | |
| SCHEMBL13870780 | 0.70 | HTT (0.36) | HTTSMN1; SMN2ALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354418-B2 | Thiazolyl-dihydro-quinazolines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-15 | — | — | US | disclosed |
| US-20090131424-A1 | THIAZOLYL-DIHYDRO-CHINAZOLINE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-21 | — | — | US | disclosed |
| US-7517995-B2 | Thiazolyl-dihydro-cyclopentapyrazole | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-14 | — | — | US | disclosed |
| US-20070238746-A1 | THIAZOLYL-DIHYDRO-CHINAZOLINE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-11 | — | — | US | disclosed |
| US-20070238730-A1 | THIAZOLYL-DIHYDRO-CYCLOPENTAPYRAZOLE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238746-A1 | THIAZOLYL-DIHYDRO-CHINAZOLINE | CYP3A7, UGT2B7, UGT1A7 | HTT 1026/4885SMN1; SMN2 3842/4885ALDH1A1 165/4885 |
| US-20090131424-A1 | THIAZOLYL-DIHYDRO-CHINAZOLINE | CYP3A7, UGT2B7, UGT1A7 | HTT 1026/4885SMN1; SMN2 3842/4885ALDH1A1 165/4885 |
| US-20070238730-A1 | THIAZOLYL-DIHYDRO-CYCLOPENTAPYRAZOLE | REN, ROR1, RORB | HTT 898/4885SMN1; SMN2 3392/4885ALDH1A1 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.